Welcome to our dedicated page for Neurogene SEC filings (Ticker: NGNE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neurogene Inc. filings document a clinical-stage biotechnology issuer developing genetic medicines for rare neurological diseases. Recent 8-K reports furnish operating results, corporate presentations, clinical and regulatory updates for NGN-401 in Rett syndrome, and material-event disclosures tied to board appointments and executive compensation arrangements.
The company's proxy materials cover director elections, board committee matters, executive compensation, equity awards, pay-versus-performance disclosure, and stockholder voting procedures. Together, the filings describe Neurogene's governance framework, common-stock compensation practices, and formal disclosures around its gene-therapy pipeline and financial condition.
PALEKAR ROHAN reported acquisition or exercise transactions in this Form 4 filing.
Neurogene Inc. director Rohan Palekar received a grant of 12,050 non-qualified stock options on February 20, 2026. These options give him the right to buy Neurogene shares if and when they vest.
The award vests in equal monthly installments over one year, with 1/12 of the options vesting each month starting March 20, 2026 and becoming fully vested by February 20, 2027, as long as he continues providing service to the company on each vesting date.
Neurogene Inc. director Robert Baffi received a grant of 12,050 non-qualified stock options on February 20, 2026. The options have a $0.00 exercise price and vest in equal 1/12 installments each month from March 20, 2026 through February 20, 2027, contingent on continued service.
Neurogene Inc. director Sarah B. Noonberg received a grant of non-qualified stock options for 12,050 shares at an exercise price of $0.00 per share. The option vests in equal monthly installments of 1/12 from March 20, 2026 until fully vested on February 20, 2027, conditioned on continued service.
Freedland Cory S. reported acquisition or exercise transactions in this Form 4 filing.
Neurogene Inc. director Cory S. Freedland reported receiving a grant of 12,050 non-qualified stock options. The options were awarded at a disclosed price of $0.0000 per option and are held directly.
The option grant vests in equal 1/12 monthly installments starting on March 20, 2026, and will be fully vested on February 20, 2027, as long as Freedland continues providing service to Neurogene on each vesting date.
Neurogene Inc. director Woods Keith reported receiving a grant of non-qualified stock options covering 12,050 shares of Neurogene common stock. This is classified as an acquisition of derivative securities as a grant or award, rather than an open-market purchase or sale.
According to the disclosure, the option vests in equal monthly installments of 1/12 of the total shares beginning on March 20, 2026, and will be fully vested by February 20, 2027. Vesting is conditioned on Keith continuing to provide services to Neurogene on each vesting date, meaning the award is tied to ongoing service over this roughly one-year period.
Neurogene Inc. has a significant institutional holder disclosing a 9.9% stake in its common stock. Redmile Group, LLC and its principal, Jeremy C. Green, report beneficial ownership of 1,557,179 shares, equal to 9.9% of the company’s common stock, including shares that could be issued from pre-funded warrants.
Those warrants are subject to a 9.99% Beneficial Ownership Limitation, which caps how many shares can be issued so their ownership does not exceed that threshold. An affiliated fund, Redmile Biopharma Investments I, L.P., reports beneficial ownership of 749,610 shares, or 4.8% of the class. The reporting persons certify the securities are not held to change or influence control of Neurogene.
Neurogene Inc. filed a current report to let investors know it has issued a new press release and updated its corporate presentation. On January 12, 2026, the company released a press statement providing recent corporate updates and anticipated milestones for the coming year, which is included as Exhibit 99.1. On the same date, Neurogene posted an updated corporate presentation on its website, furnished as Exhibit 99.2. The company notes that this information is being furnished, not filed, under the Exchange Act, meaning it is not automatically subject to certain liability provisions or incorporated into other SEC filings unless specifically referenced.
Neurogene Inc. (NGNE) reported that it issued a press release with financial results for the quarter ended September 30, 2025 and posted an updated corporate presentation. Both materials, dated November 13, 2025, are furnished with this report as Exhibits 99.1 (press release) and 99.2 (presentation). The information under Item 2.02 and these exhibits is furnished and not deemed filed under the Exchange Act.
Neurogene Inc. (NGNE) filed its Q3 2025 10‑Q, reporting a net loss of $20.953 million as operating expenses rose with advancing gene therapy programs. Revenue was none. Research and development expense was $17.241 million and general and administrative expense was $6.557 million; other income contributed $2.845 million. Net loss per share was $0.99.
Liquidity remains strong with cash, cash equivalents and short‑term investments totaling $265.4 million as of September 30, 2025. Year‑to‑date operating cash use was $59.7 million. The company sold 500,000 shares via its at‑the‑market program for $9.8 million net in September, and subsequently raised $20.6 million net from 700,000 shares in October.
Program updates: the registrational Embolden trial of NGN‑401 for Rett syndrome began dosing its first participant in Q4 2025 after FDA alignment on key design elements; NGN‑401 holds RMAT designation and is in FDA’s START pilot. Interim Phase 1/2 data (pediatric cohort at the 1E15 vg dose) showed multidomain developmental gains and a tolerability profile with only Grade 1–2 treatment‑related AEs. Shares outstanding were 14,775,285 as of September 30, 2025; 15,489,800 as of November 11, 2025.
Neurogene Inc. (NGNE) furnished an Item 7.01 update announcing positive, updated interim clinical data from the pediatric (ages 4–10) cohort of its ongoing Phase 1/2 trial of NGN-401 gene therapy for females with Rett syndrome. The company also posted a related corporate presentation. A press release (Exhibit 99.1) and the presentation (Exhibit 99.2) were furnished, not filed, on November 12, 2025.